DiaGenic provides update on key clinical programs
DiaGenic announces that the validation study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage, has failed to reach the study goals. Consequently, DiaGenic will not pursue CE-marking or U.S. trials with the current version of MCItect®. The clinical study for the company’s other key product AMYtect™ has successfully recruited 100 patients and will enter the analysis phase in August.In the development of MCItect®, DiaGenic reported results on July 17th 2012 from a 60-patient study demonstrating a total prediction accuracy of 74% in detecting